Clinical Trials Logo
  1. Home
  2. C3 Glomerulopathy
  3. NCT03369236

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy Clinical Trial

Official title:
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label Extension

Clinical Trial Summary

The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03369236
Study type Interventional
Source Alexion Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date June 12, 2018
Completion date December 18, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03955445 - Long-term Efficacy, Safety and Tolerability of LNP023 in C3G Phase 3
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Not yet recruiting NCT05647811 - Study of NM8074 in Adult C3 Glomerulopathy Patients Phase 1/Phase 2
Active, not recruiting NCT05067127 - Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT05809531 - An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Recruiting NCT06209736 - Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN Phase 2
Terminated NCT03459443 - A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Phase 2
Active, not recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Recruiting NCT02682407 - Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Phase 2
Recruiting NCT05083364 - Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease Phase 1
Completed NCT03723512 - Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study N/A
Completed NCT03124368 - A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Phase 2
Available NCT04729062 - C3G/Primary IC-MPGN EAP